Physician profile
Ward Dean
NPI 1871877191
$4,309.76
in general payments reported to CMS, 2019-2025
12 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $714 · 2021: $800 · 2022: $680 · 2023: $773 · 2024: $471 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Education: $38.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.92 |
| Education | $38.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,827.49 | 2020-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $1,207.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $478.64 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $280.69 | 2021-2023 | |
| Antares Pharma, INC. | $262.78 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Axsome Therapeutics, INC. | $95.72 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $74.31 | 2021 | |
| Pfizer INC. | $21.44 | 2021 | |
| Halozyme INC | $17.93 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.33 | 2021 | |
| Endo Pharmaceuticals INC. | $14.38 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ward Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.